AEterna's Phase III Cetrorelix Trial Fails.
TORONTO (DOW JONES)--AEterna Zentaris Inc. (AEZS) suffered a big setback Monday after announcing the failure of a highly-anticipated Phase III trial of its cetrorelix drug in benign prostatic hyperplasia, or BPH.
Full Story